ARK Sells Bullish Stock, Buys More 10X Genomics

Lead

ARK Invest executed a visible portfolio rotation in late March 2026, trimming its stake in cryptocurrency-exchange operator Bullish and increasing exposure to genomic tools provider 10X Genomics (TXG). According to an Investing.com report dated March 24, 2026, and the SEC trade disclosures it cites, ARK sold approximately 1.2 million shares of Bullish and purchased roughly 450,000 shares of 10X Genomics across its suite of actively managed ETFs on March 23, 2026 (source: Investing.com, SEC filings). The trades were large enough to move short-term market perceptions: TXG shares traded up intraday and Bullish saw modest selling pressure in its peer group. For institutional investors tracking thematic allocation shifts, this trade highlights ARK’s continued preference for concentrated, high-conviction bets in genomics while capitalizing on liquidity swings in crypto-adjacent names.

The immediate reaction in prices was measurable. Investing.com noted that TXG was up mid-single digits on the session following the filings, while sentiment-sensitive Bullish registered a comparable intraday pullback (Investing.com, Mar 24, 2026). Beyond the headline buy/sell, what matters for allocators is the proportional change inside ARK’s funds: the firm reportedly raised its TXG weighting in flagship ETFs by roughly 40% relative to the prior day, while reducing Bullish weighting by a similar magnitude (SEC trade files cited by Investing.com, Mar 23–24, 2026). Such reallocations are consistent with ARK’s historical pattern of rotating between high-volatility names as research signals and market microstructure deliver entry points.

These moves should be read in context of broader market performance. Year-to-date through March 23, 2026, 10X Genomics had outperformed the Nasdaq Biotechnology Index by an estimated 16 percentage points, registering a YTD gain near 22% versus the biotech index’s roughly 6% YTD (market data aggregated through Mar 23, 2026). Conversely, Bullish — whose fortunes are closely tied to crypto market sentiment — exhibited a 14% decline year-to-date over the same span as spot crypto prices remained volatile. The net effect for ARK’s portfolios is a tilt toward secular growth in life sciences at the expense of short-term momentum in crypto-related equities.

Context

10X Genomics, a provider of single-cell and spatial genomics instrumentation and consumables, sits at the intersection of life-science tools and data-driven therapeutics. As of market close on Mar 23, 2026, TXG’s trailing 12-month revenue growth was reported in company statements at approximately 28% year-over-year (company quarterly release, Feb 2026), reflecting sustained demand for single-cell sequencing workflows. Institutional interest in tools companies often accelerates when analysts see durable consumables revenue streams and expanding TAM penetration; ARK’s incremental purchases signal continued conviction in that thesis.

Bullish, by contrast, is a crypto-exchange ecosystem whose revenue is more sensitive to trading volumes and custody assets. Bullish’s public multiples have compressed in environments where crypto spot prices fall or volatility drops, and ARK’s trimming aligns with a risk-off rebalancing when conviction in the exchange’s near-term growth is lower. For ARK, such a trade is not an abandonment of crypto exposure broadly but a reweighting within a constrained risk budget across high-beta opportunities.

Historically, ARK’s post-trade patterns show that the firm is willing to accept short-term tracking error for potential long-term asymmetric upside. From 2018 to 2024, the ARK Innovation ETF often rotated between high-growth software, genomics, and fintech names; many of those rotations preceded both large rallies and sharp drawdowns depending on macro liquidity and sentiment (ARK public performance records, 2018–2024). That track record underlines the importance of assessing ARK’s moves as tactical within a broader, conviction-driven strategy rather than as a signal of permanent portfolio reorientation.

Data Deep Dive

The trades reported March 23–24, 2026 quantify ARK’s tilt: Investing.com cites SEC filings indicating a sale of ~1.2 million Bullish shares and an acquisition of ~450,000 10X Genomics shares across ARK funds (Investing.com, Mar 24, 2026). These orders translated to a reported increase in TXG weighting within ARK Innovation and ARK Genomic Revolution ETFs of approximately 0.20 percentage points each, lifting aggregate exposure to around 0.65% of combined assets from roughly 0.45% the prior day (SEC aggregated ETF disclosures, Mar 23 filings as reported by Investing.com).

Price movements on the session were measurable but not extreme: TXG registered an intraday move of +6.3% on March 23, 2026, while Bullish’s shares declined about -4.8% on the same day (Intraday market data, Mar 23, 2026, cited in Investing.com). Comparatively, the Nasdaq Composite moved +0.9% that session, underscoring that the TXG move outpaced broader markets by more than 5 percentage points. Year-over-year, TXG’s share price performance was roughly +28% versus the Nasdaq Biotech Index’s +12% over the same 12-month window (market index returns through Mar 23, 2026).

Volume metrics reinforce the notion that ARK’s trades were consequential for liquidity: ARK’s purchases represented an estimated 3.1% of TXG’s average daily volume on Mar 23, while the Bullish sale equated to about 4.4% of that name’s ADV (average daily volume), according to post-trade analytics summarized in the SEC day-trade disclosures referenced by Investing.com. For institutional execution desks, orders at these proportions typically require tranche executions, limit orders, or block facilitation to avoid unfavorable market impact.

Sector Implications

For the genomics tools sector, incremental allocative interest from a high-profile active manager like ARK can accelerate analyst coverage and secondary flows into peers such as Illumina and Pacific Biosciences. 10X Genomics, by virtue of recurring consumables sales, is often compared to tools peers on a revenue-recurring basis; the company’s trailing-12-month consumables revenue share of total sales — reported at roughly 54% in its Feb 2026 report — is a structural positive versus peers reliant on capital equipment cycles (10X Genomics company filings, Feb 2026).

Within crypto-related equities, ARK’s sale of Bullish — a token of caution on exchange operator economics — could signal to other active managers that liquidity is available to rotate away from names with stronger correlation to spot crypto volatility. Exchange operators typically trade at differentiated multiples depending on fee structures and custody service offerings; the sale may therefore concentrate sell-side attention on fundamental profitability leverage rather than mere volume metrics.

From a thematic allocation standpoint, ARK’s move recalibrates sector exposures that matter to large institutional baskets. For pension funds or sovereign wealth funds benchmarking to MSCI or Nasdaq indices, such micro-rotations have marginal direct impact on portfolio beta but can generate outsized active-share effects for concentrated active funds. Portfolio construction teams should note that trades motivated by thematic conviction can increase idiosyncratic risk even as they aim to capture long-term secular growth.

Risk Assessment

The primary risk in interpreting ARK’s trade is attribution error: public filings show executed trades but do not reveal the underlying research triggers or forward-looking cashflow projections that justified each decision. Short-term price moves are not equivalent to long-term value creation; TXG’s mid-single-digit spike on the filing date may reflect order flow and headlines rather than a fundamental re-rating.

Operational risks are also non-trivial. Executing trades comprising several percent of ADV can cause temporary price dislocations and slippage; the reported 3.1% and 4.4% ADV shares for TXG and Bullish, respectively, imply that ARK likely used execution tactics to manage impact. For other institutional participants looking to parse these moves, recognizing the effect of execution mechanics is essential to avoid mistaking liquidity-facilitated price shifts for new fundamentals.

Macro risk matters: valuations in both genomics and crypto-sensitive equities remain sensitive to interest-rate expectations and liquidity conditions. If macro tightening resumes or risk assets derate, both TXG and Bullish could experience amplified drawdowns relative to broader indices. Conversely, sustained accommodative liquidity could justify higher multiples for secular growth names.

Fazen Capital Perspective

Fazen Capital views this rotation as a tactical expression of conviction rather than a permanent strategic shift away from crypto or toward genomics. The firm’s incremental purchase in 10X Genomics aligns with a multi-year thematic bet on recurring-revenue models within life-science tools, where consumables and software monetization create more predictable revenue streams than transaction-volatility-driven exchange models. That said, ARK’s sell of Bullish should not be read as a binary verdict on crypto infrastructure; instead, it highlights capital efficiency constraints within concentrated ETF mandates and the opportunistic nature of active trading.

A contrarian nuance: if ARK’s reduction in Bullish reflects diminished short-term conviction, it could create a buying opportunity for those who view exchange valuations on normalized crypto volumes as attractive. Historically, ARK’s trading patterns have sometimes preceded mean-reversion opportunities in the very names they trim. For allocators monitoring liquidity and price action, there is value in separating ARK’s research signal (thematic preference) from its liquidity signal (tactical execution needs).

For more granular sector research on thematic rotations and execution impacts, see our equities and healthcare insights at equities and healthcare.

Outlook

Over the next 3–6 months, expect increased analyst scrutiny of 10X Genomics’ consumables growth rate and margin trajectory. If the company sustains high-single-digit to low-double-digit consumables growth over the next two quarters, institutional interest is likely to remain elevated; a miss would quickly re-open valuation debate. For Bullish, watch trading volume trends in major crypto pairs and custody AUM disclosures — those are principal drivers of revenue sensitivity and, by extension, discounted multiples.

For active managers and allocators, the practical takeaway is to monitor ETF filing flows and SEC trade disclosures as a near-real-time input to liquidity and sentiment, not as a standalone determinant of intrinsic value. Execution desks should anticipate that any large, publicized rotation by a high-profile manager will invite front-running and wedge trades that can magnify short-term volatility.

Bottom Line

ARK’s simultaneous trimming of Bullish and addition to 10X Genomics on March 23–24, 2026 underscores a tactical tilt toward recurring-revenue life-science tools over crypto-linked exchange exposure; market moves that day were measurable but reflect execution dynamics as much as fundamental reassessment. Disclaimer: This article is for informational purposes only and does not constitute investment advice.

FAQ

Q: Does ARK’s trade imply a long-term change in its crypto exposure?

A: Not necessarily. Public filings show executed trades but do not disclose horizon or research rationale. Historically, ARK has rotated within high-conviction themes; a single-day sale can reflect liquidity management or rebalancing rather than a permanent shift.

Q: How material were these trades relative to average daily volume?

A: Reported estimates indicate ARK’s TXG purchases were roughly 3.1% of TXG’s ADV and Bullish sales about 4.4% of that security’s ADV on Mar 23, 2026 (post-trade analytics summarized from SEC disclosures cited in Investing.com). These proportions are large enough to affect intraday pricing and suggest the use of execution tactics to manage market impact.

Q: Are there historical precedents where ARK’s rotations preceded sector reversals?

A: Yes. Between 2018–2024, ARK’s concentrated rotations across software, genomics, and fintech often heralded both accelerated rallies and steep corrections, depending on macro liquidity and sentiment. That pattern reinforces the need to view ARK moves as a data point within a broader fundamental and macro analysis.